ClinicalTrials.gg
CompletedNCT02103322Updated Jun 27, 2014

Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions

A Phase 2/3 interventional study of Imatinib Mesylate Tablets, 400 mg and Imatinib Mesylate Tablets, 400 mg in Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor, sponsored by Amneal Pharmaceuticals, LLC. Completed at 5 sites in India. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Amneal Pharmaceuticals, LLC · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
45th of 83
48 · median 60
Started
2014
with 3 others
Phase 2/3
Only one
of the 93
Registered
79th of 93
by date
Lead sponsor
1 of 93
Amneal Pharmaceuticals, LLC

Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 45th largest by enrollment of the 83 interventional ones that give a count, is one of 4 that started in 2014, is the only one in phase 2/3, and was the 79th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

To characterize pharmacokinetic profile of test product compared to that of the corresponding reference product in adult patients, who are diagnosed to have Chronic Myeloid Leukemia \& Gastrointestinal Stromal Tumor under Fed Conditions.

Read the detailed description

To characterize pharmacokinetic profile of Imatinib Mesylate tablets EQ 400 mg base of Amneal Pharmaceuticals LLC, compared to that of the reference product - GLEEVEC® (imatinib mesylate) tablets 400 mg in adult patients, who are diagnosed to have CML or GIST and are presently receiving stable dose of imatinib mesylate tablets 400 mg, and assess their bioequivalence.

03

Conditions studied

  • Chronic Myeloid Leukemia
  • Gastrointestinal Stromal Tumor
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 55 years (both inclusive) and either sex
  • Diagnosed case of Philadelphia chromosome positive (Ph+) CML patients in chronic phase or GIST and presently being treated with imatinib 400 mg tablets.
  • Willing to give written for participation in the study as well as willing and able to comply with study visit schedule and other protocol requirements.
  • Female patients of child bearing potential (except for those who have completed one year since menopause or have gone through hysterectomy or bilateral tubal ligation) must have negative serum pregnancy test at the screening, negative urine pregnancy test on check in to housing, must be non-lactating at screening and must agree to use effective (barrier or hormonal) for the study period.

Exclusion criteria

Exclusion Criteria:

  • History of to imatinib mesylate or to any of the as judged by investigator.
  • Patient of CML receiving treatment in Myeloid Blast Crisis or Accelerated Phase
  • Abnormal laboratory results as below:
  • History of a heart failure, renal insufficiency, hypereosinophilic syndrome (HES), myelodysplastic syndrome (MDS)/ myeloproliferative disease (MPD) or acute systemic mastocytosis (ASM).
  • History of therapy with any of the following as per timelines before randomization: inducers of activity and inhibitors of CYP3A4 activity, within 14 days, product/device within last one month
  • Alcohol or any drug dependence within past one year.
  • Blood donation/loss exceeding 200 ml within last 60 days.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Imatinib Mesylate Tablets, 400 mg

    Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.

    Drug: Imatinib Mesylate Tablets, 400 mg

  • Active comparator
    Gleevec Tablets, 400 mg

    Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.

    Drug: Imatinib Mesylate Tablets, 400 mg

Interventions

  • DrugImatinib Mesylate Tablets, 400 mg

    Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.

  • Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with "400" on one side with score on the other side, and "SL" on each side of the score.

    Also known as: Gleevec

06

What researchers measure

Primary outcomes

  1. Cmax

    Peak maximum concentration over dosing interval in the steady state

    Time frame: Days 5, 6, 7, 12, 13, 14 and 15

  2. AUC0-tau

    The area under the blood concentration curve versus time, calculated by the trapezoid method, from zero time to the dose interval (tau) in the steady state

    Time frame: Days 5, 6, 7, 12, 13, 14 and 15

Secondary outcomes

  1. Tmax

    The time to reach such peak over dosing interval in the steady state

    Time frame: Days 5, 6, 7, 12, 13, 14 and 15

  2. Cmin

    Minimum concentration established at each dose interval end of the steady state

    Time frame: Days 5, 6, 7, 12, 13, 14 and 15

  3. Cavg

    Average concentration in the steady state (= AUC0-tau / tau)

    Time frame: Days 5, 6, 7, 12, 13, 14 and 15

  4. Swing

    Swing in steady state pharmacokinetics, calculated as (CmaxSS-CminSS)/ CminSS

    Time frame: Days 5, 6, 7, 12, 13, 14 and 15

  5. Fluctuation Rate

    Degree of fluctuation in the steady state pharmacokinetics, calculated as (Cmax-Cmin)/CavSS

    Time frame: Days 5, 6, 7, 12, 13, 14 and 15

07

Study locations

5 sites
  • Kailash Cancer Hospital & Research Centre
    Vadodara, Gujurat 391760, India
  • Srinivasam Cancer Care Hospitals India Pvt.
    Bangalore, Karnataka 560076, India
  • Karnataka Caner Hospital
    Bengaluru, Karnataka 560096, India
  • Lokmaya Hospital
    Pune, Maharashtra 411044, India
  • Dr. G Viswanathan Speciality Hospitals
    Tiruchirappalli, Tamil Nadu 620 008, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Mar 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2014
First posted
Apr 3, 2014
Start
Feb 2014
Primary completionActual
Mar 2014
CompletionActual
Jun 2014
Results delay requested
Jun 25, 2014
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02103322
Collaborators
Accutest Research Laboratories (I) Pvt. Ltd.
Responsible party
Sponsor
First posted
Apr 3, 2014
Start date
Feb 2014
Primary completion
Mar 2014
Completion
Jun 2014
Last update
Jun 27, 2014

Study contacts

Ashutosh Jani, MD
principal investigator · Accutest Research Laboratories (I) Pvt. Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion